LOS ANGELES, May 20, 2024 /PRNewswire/ — Ispire Technology Inc. (“Ispire” or the “Company”) (NASDAQ: ISPR), a leader in the development and commercialization of vaping technology and precision dosing, announced that Jim McCormick has been appointed Chief Financial Officer. The Company also announced the appointments of: John Patterson as Senior Vice President of International Nicotine; Dennis Lider as Senior Vice President of Cannabis Product Sales; and David Hessler as Senior Vice President of Operations.

“We’re thrilled to announce this significant talent upgrade at Ispire as we gear up for rapid expansion both domestically and internationally,” said Ispire’s Co-Chief Executive Officer Michael Wang. “We are delighted to welcome Jim, John, David and Dennis aboard as valuable additions to our team. These strategic moves underscore our commitment to driving innovation and our growth as we grow globally.”

Wang added, “Jim embodies dynamism in executive leadership, with a remarkable career spearheading financial and business operations worldwide. As we drive Ispire’s mission of being a worldwide leader in R&D, design, commercialization, manufacturing, sales, marketing and distribution for branded and ODM solutions for the e global vaping and cannabis industries, Jim brings a unique fusion of entrepreneurial zeal and operational prowess essential for scaling our business.”

“As someone who has admired Ispire’s dedication to client value over the years, I look forward to collaborating with Michael and the executive team to further enhance Ispire’s achievements not only in the U.S. but also in diverse markets worldwide,” said Ispire CFO Jim McCormick.

Chief Financial Officer Jim McCormick

Jim McCormick brings more than three decades of diverse leadership experience to his new role. He started his career in public accounting with KPMG Peat Marwick in 1989, transitioning to consumer goods with Mid-America Pepsi-Cola and later joining British American Tobacco’s (BAT) associate company Brown & Williamson Tobacco in 1992. More than a dozen years at BAT, he held various international general management and CFO positions across Europe, South America, Southeast Asia, Sub-Saharan Africa, and Northern Africa. In 2009, he returned to the US, holding CFO roles in Federal Flange Inc. and Sodexo’s Corporate Service division. He later joined ECIG, a publicly traded vaping products company, before serving as COO and CFO of KushCo Holdings Inc. from August 2017 to January 2019, and as president of Ignite International Inc. until December 2019. Most recently, he has provided consultancy services to several companies, including UMBRLA, Inc., Redbird Bioscience, Cars & Credit Master, Abstrax Tech Inc., and Thought Leaders, Inc., focusing on the heated tobacco sector. Jim holds a B.S. in Finance and Accounting from Eastern Illinois University (1988) and an MBA from Southern Illinois University Edwardsville (1992). He is also a Certified Public Accountant (CPA), Certified Management Accountant (CMA), and Certified Internal Auditor (CIA), though currently inactive.

Senior Vice President of International Nicotine John Patterson

John Patterson brings more than 25 years of extensive experience in the tobacco and next-generation nicotine categories, spanning both US domestic and international markets, notably in the UK and the EU. Beginning his career at Altria, John has since held pivotal roles across Europe for Philip Morris International, NJOY and most recently Juul Labs, where he served as Senior Director and Country Manager for the United Kingdom. As a dynamic and thoughtful leader, John boasts over two decades of experience surpassing commercial targets and driving sales growth while effectively managing costs. With a keen strategic mindset and strong operational acumen, he has navigated diverse countries, cultures and trade sectors, successfully turning around struggling brands and establishing credible start-ups.

Senior Vice President of Cannabis Product Sales Dennis Lider

With more than 20 years of CPG sales leadership experience, Dennis Lider joins Ispire, boasting over a decade of executive leadership in revenue management. Since 2019, he has held senior-level positions with publicly traded cannabis companies, overseeing wholesale, retail, and distribution sales functions. Dennis brings a wealth of experience in international market expansions, corporate business development, global sales management, and channel diversification. He will be based in FL, ensuring that the east coast growth aligns with the success Ispire has achieved with its west coast legacy partners.

Senior Vice President of Operations David Hessler

David Hessler, Senior Vice President of Operations, began his career in California’s shipping industry after graduating from Georgetown University’s School of Foreign Service. His journey led him to Moscow in 1992, where he spent two decades in the global cigarette industry with PMI and JTI. At JTI’s Global Supply Chain organization, David led its Global Customer Service Department in Geneva, Switzerland, managing operations across 190 markets with over 5000 SKUs. He also oversaw Asia-Pacific supply chain and manufacturing functions, including JTI Petro in St. Petersburg, Russia, the world’s largest cigarette factory outside China, producing 87 billion cigarettes annually valued at over $5 billion. In 2017, David transitioned to the cannabis industry, serving as President Manufacturing at Grupo Flor in Salinas, CA. Recently, he was CEO at Swiss Tech Labs in Montreux, Switzerland, exclusive European supplier of CBD products to Oettinger Davidoff AG of Basel, a leading luxury cigar manufacturer.

About Ispire Technology Inc.

Ispire is engaged in the research and development, design, commercialization, sales, marketing, and distribution of branded e-cigarettes and cannabis vaping products. The Company’s operating subsidiaries own or license more than 500 patents received or filed globally. Ispire’s tobacco products are marketed under the Aspire brand name and are sold worldwide (except in the U.S., People’s Republic of China and Russia) primarily through its global distribution network. The Company’s cannabis products are marketed under the Ispire brand name primarily on an original design manufacturer (ODM) basis to other cannabis vapor companies. Ispire sells its cannabis vaping hardware only in the U.S., and it recently commenced its marketing activities in Canada and Europe. For more information, visit www.ispiretechnology.com or follow Ispire on  Instagram, LinkedIn, Facebook, Twitter and YouTube.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (“Securities Act”) as well as Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, as amended, that are intended to be covered by the safe harbor created by those sections. Forward-looking statements, which are based on certain assumptions and describe the Company’s future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as “believe,” “expect,” “may,” “will,” “should,” “would,” “could,” “seek,” “intend,” “plan,” “goal,” “project,” “estimate,” “anticipate,” “strategy,” “future,” “likely” or other comparable terms, although not all forward-looking statements contain these identifying words. All statements other than statements of historical facts included in this press release regarding the Company’s strategies, prospects, financial condition, operations, costs, plans and objectives are forward-looking statements. Important factors that could cause the Company’s actual results and financial condition to differ materially from those indicated in the forward-looking statements. Such forward-looking statements include, but are not limited to, risks and uncertainties including those regarding: the Company’s ability to collect its accounts receivable in a timely manner, the Company’s business strategies, the ability of the Company to market to the Ispire ONE, Ispire ONE’s success if meeting its goals, the ability of its customers to derive the anticipated benefits of the Ispire ONE and the success of their products on the markets; the Ispire ONE proving to be safe, and the risk and uncertainties described in “Risk Factors,” “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” “Cautionary Note on Forward-Looking Statements” and the additional risk described in Ispire’s Annual Report on Form 10-K for the year ended June 30, 2023 and any subsequent filings which Ispire makes with the U.S. Securities and Exchange Commission. You should not rely upon forward-looking statements as predictions of future events. The forward-looking statements made in the press release relate only to events or information as of the date on which the statements are made in the press release. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events except as required by law. You should read this press release with the understanding that our actual future results may be materially different from what we expect.

Investor Relations and Media Contacts:

For more information, kindly contact:

Investor Relations Contact:
Phil Carlson
ispire@kcsa.com

Media Contact:
Ellen Mellody
570-209-2947
ispire@kcsa.com

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

Fort Lauderdale, Florida–(Newsfile Corp. – March 25, 2024) – Flora Growth Corp. (NASDAQ: FLGC) (“Flora” or the “Company”), a cannabis focused consumer-packaged goods leader and pharmaceutical distributor serving all 50 states and 28 countries with 20,000+ points of distribution around the world, plans to launch a cannabis home grow kit, start up material seeds and cuttings in Germany in response to the first phase of Germany’s new recreational cannabis legalization law.

The German legal cannabis recreation market has the potential to reach $4.2 billion upon legalization with the total European market forecasted to achieve revenues of $10.2 billion. The Company estimates the potential value of the home grow market in Germany to reach $400 million after legalization.

The Company’s existing seedbank, which is the arguably the largest globally, and the over 200 strains held within, including several world-class genetics and winners of Cannabis Cups, is expected to be a key component to the Company’s strategy.

Flora’s wholly-owned subsidiaries have been active in Germany since 2017, obtained the first medical cannabis license in Germany and are responsible for selling the first gram of medical cannabis in the country.

Effective April 1, 2024, adults over the age of 18 in Germany are to be allowed to possess up to 50 grams of cannabis for private consumption and grow up to three plants. The Company intends to address the market demand for home grow and establish itself as a genetics provider in the country. Adults will be allowed to join nonprofit social clubs with a maximum of 500 members each starting July 1, 2024. Individuals will be allowed to buy up to 25 grams per day, or a maximum of 50 grams per month. The Company plans to supply social clubs with start up material in the form of seeds and cuttings.

In other markets where recreational cannabis was been legalized, such as Canada, studies have demonstrated that almost one in ten cannabis consumers reported home cultivation, with modest increases following legalization and most growing within the legal limit of plants per person.

The cannabis home grow kit, select genetics and cuttings on a limited quantity basis and for personal use for the German marketplace are expected to be available at justcbdstore.de, as well as at preferred partners.

“We are carefully examining Germany’s new legislation for immediate business opportunities. What Canada’s legalization case has taught us is that a notable percentage of adults reported home cultivation of cannabis immediately following legalization. We believe German adults will exhibit a similar pattern and we intend to give them the tools to do,” said Clifford Starke, Chief Executive Officer.

###

About Flora Growth Corp.

Flora Growth Corp. is a cannabis focused consumer-packaged goods leader and pharmaceutical distributor serving all 50 states and 28 countries with 20,000+ points of distribution around the world. For more information on Flora, visit www.floragrowth.com.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

LOS ANGELES, Feb. 21, 2023 (GLOBE NEWSWIRE) — Irwin Naturals Inc. (CSE: IWIN) (OTC: IWINF) (FRA: 97X) (“Irwin” or the “Company”) is pleased to announce the Company has successfully completed the acquisition of Serenity Health, LLC, (“Serenity”) one of the leading ketamine clinics in Louisville, KY. The agreement with Serenity was initially announced November 30, 2022. The acquisition, completed on February 16, 2023, marks two key milestones in Irwin’s Emergence clinics growth strategy in the mental health industry. First, the acquisition is expected to be immediately accretive increasing the company’s annualized EBITDA by double digits and second, the addition of this clinic further demonstrates Irwin’s ability to attract profitable clinics as part of its goal to establishing the world’s largest network of psychedelic mental health clinics.

Klee Irwin, the CEO of Irwin Naturals, “With each clinic we bring under the Irwin Naturals Emergence umbrella, we establish our leadership in this innovative approach to mental healthcare. As the first household name to enter this space, we are advancing rapidly towards our goal of becoming the market’s first mover.”

The acquisition of Serenity Health by Irwin Naturals Emergence is a strategic move aimed at providing accessible and affordable mental healthcare to patients. This acquisition brings the total number of clinics under the Irwin Naturals Emergence umbrella which are either under a definitive agreement, the Braxia LOI or acquired to 22, including existing clinics in Florida, Vermont, New Hampshire, Iowa, and Georgia.

Irwin Naturals Emergence also recently declared their intent to acquire Braxia Scientific Corp. Braxia (“Braxia Scientific”), (CSE: BRAX) (OTC: BRAXF) (FWB: 4960), a medical research company providing psychiatric, innovative ketamine and psilocybin treatments for mental health disorders (“Braxia LOI”). The two entities coming together will create a new market leader in multiple markets across the United States and Canada.

Transaction Terms

The total consideration will be paid in upfront and deferred consideration. Also included are contingent payments based on milestones related to expansion and profitability goals.

About Irwin Naturals

Irwin Naturals has been a household name and best-in-class nutraceutical formulator since 1994. It is now leveraging its household name to enter into the cannabis and psychedelic sectors. Irwin has operated profitably for over 28 years¹. The Company’s growing portfolio of products is available in more than 100,000 retail doors across North America, where over 100 million people know the Irwin Naturals brand.² In 2018, the Company first leveraged its brand to expand into the cannabis industry by launching hemp-based CBD products into the mass market. The Company is now leveraging its brand trust with an objective to become one of the first household names in THC-based products and the world’s largest chain of psychedelic mental health clinics. Irwin Naturals became a publicly traded company on the Canadian Securities Exchange (CSE) in August 2021. The Company’s shares began to be traded on the OTCQB Venture Market in November 2021. More information on the Company’s stock can be found via Bloomberg as well as the Wall Street Journal.

For investor-related information about the Company, please visit ir.irwinnaturals.com/

To contact the Company’s Investor Relations department, please call toll-free at (800) 883-4851 or send an email to Investors@IrwinNaturals.com.

“Klee Irwin”
________________________________
Klee Irwin
Chief Executive Officer
T: 310-306-3636
investors@irwinnaturals.com

IR Information

Press Contact

Irwin Naturals Investor Relations
Cassandra Bassanetti-Drumm
T: 310-306-3636
investors@irwinnaturals.com

Regulatory Overview

The following is a brief summary of regulatory matters concerning ketamine in the United States (“US”). Under the Controlled Substances Act (21 U.S.C. § 811) (the “CSA”), ketamine is currently a Schedule III drug as well as being listed under the associated Narcotic Control Regulations and psilocybin is currently a Schedule I drug.

Most US States have enacted Controlled Substances Acts (“State CSAs”) which regulate the possession, use, sale, distribution, and manufacture of specified drugs or categories of drugs and establish penalties for State CSA violations and form the basis for many state and
local drug laws enforcement activity. State CSAs have either adopted drug schedules identical or similar to the federal CSA schedules or, in some instances, have incorporated the federal scheduling mechanism. Among other requirements, some US States have established a prescription drug monitoring or review programs collect information about prescription and dispensing of controlled substances for the purposes of monitoring, analysis and education.

In the United States, facilities holding or administering controlled substances must be registered with the US Drug Enforcement Agency (“DEA”) to perform this activity. As such, medical professionals and/or the clinics in which they operate, as applicable, are also required to have a DEA license to obtain and administer ketamine (a “DEA License”). While ketamine is a controlled substance in the United States, it is approved for general anesthetic induction under the US Food, Drug, and Cosmetic Act. Once a drug is approved for use, physicians may prescribe that drug for uses that are not described in the product’s labeling or that differ from those tested by the manufacturer and approved by the Food and Drug Administration (the “FDA”). Licensed medical practitioners may prescribe ketamine legally in Canada or the United States where they believe it will be an effective treatment in their professional judgment.

Please see Irwin’s filing statement on its SEDAR profile for more information on the regulatory environment and regulations surrounding the US ketamine industry.

Forward-Looking Information

This news release contains certain forward-looking statements that reflect the current views and/or expectations of management of the Company with respect to performance, business and future events. Forward-looking statements can often be identified by words such as “may”, “will”, “would”, “could”, “should”, “believes”, “estimates”, “projects”, “potential”, “expects”, “plans”, “intends”, “anticipates”, “targeted”, “continues”, “forecasts”, “designed”, “goal”, “objective,” or the negative of those words or other similar or comparable words. Forward-looking statements are based on the then-current expectations, beliefs, assumptions, estimates and forecasts about the business and the industry and markets in which the Company operates. Forward-looking statements in this news release include statements related to information concerning the ability of the Company to perform the terms of the transaction referenced herein; the receipt of all necessary approvals, including regulatory approvals; expectations for other economic, market, business and competitive factors; and the Company actually entering into and doing business, and continuing to do such business in the U.S. cannabis and psychedelics markets. The potential entrance by the Company into these new business segments are in their preliminary stages and may be subject to approval from the board of directors of the Company as well as any regulatory approval, including that of the Canadian Securities Exchange. These statements are based on numerous assumptions that are believed by management to be reasonable in the circumstances, and are subject to a number of risks and uncertainties, including without limitation: board and regulatory approval, including the approval of the Canadian Securities Exchange; Irwin being able to acquire and/or enter into business relationships to enter into these new markets; the Company obtaining the required licenses; and changes to regulations and laws regarding cannabis or psychedelics; binding agreements that formalize the terms of the non-binding letter of intent described in the Braxia press release.. Further information on the regulatory environment and risks will be contained in future disclosures. Forward-looking statements are subject to a number of known and unknown risks, uncertainties, and other factors that may cause actual results, performance, or achievements to be materially different from that which are expressed or implied by such forward-looking statements. Forward-looking statements are not guarantees of future performance and involve risks, uncertainties, and assumptions which are difficult to predict. Accordingly, readers should not place undue reliance on forward-looking statements and information, which are qualified in their entirety by this cautionary statement. The Company does not undertake any obligation to release publicly any revisions for updating any voluntary forward-looking statements, except as required by applicable securities law.

Neither the CSE nor its Market Regulator (as that term is defined in policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

SOURCE: Irwin Naturals Inc.

¹ Under several corporate structures, Klee Irwin has operated the Irwin brand profitably since 1994, as measured by EBITDA adjusted for extraordinary costs.
² Consumer brand recognition information is based on a Company survey with a sample size of 500 randomly selected adults.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

KINGSVILLE, ON, Nov. 30, 2022 /CNW/ – Greenway Greenhouse Cannabis Corporation (CSE: GWAY) (“Greenway” or the “Company”) a cultivator of high-quality greenhouse cannabis for the Canadian market, is pleased to announce the completion of its expansion to 167,000 ft2 of growing space, and its submitted application to trade on the OTCQB Markets (the “OTCQB”)

Expansion: On time, on budget

“Our team is proud to be able to say we have finished our full 132,000 ft² expansion on time and on budget. As a leadership team, we promised shareholders we could do it, and we have fulfilled that promise.” Said Jamie D’Alimonte, CEO of Greenway. “The expansion allows us to quadrupole our output up to 24,000 KG, moving Greenway another step down the pathway to significant profitability.”

“We have to thank our team and contractors who helped us deliver this expansion on time and on budget,” said Carl Mastronardi, President of Greenway. “Our current customers will be pleased to know we have more of the consistent product that they have grown to appreciate, and we are looking forward to widening our customer base.” The Company notes that an application to Health Canada to amend the licensed square footage will be submitted shortly.

OTCQB Markets

The Company is also pleased to announce it has submitted an application to the OTCQB, to broaden the investment opportunity to the United States of America. Greenway will be trading under GWAYF on the OTCQB, and should be available to the public imminently.

“Expanding our potential investor base into the U.S.A. should provide more coverage and more trading volume,” said CFO, Darren Peddle. “Management has the legacy of scaling, producing and shipping over 44 million pounds of produce annually, almost 75% of that to the U.S.A. We are pleased to be able to introduce Greenway as a company looking to build itself up to a similar stature, combining consistency with profitability.”

Business Development – Contracts to Grow

Due to the reputation that the Company has fostered for consistent, high quality cannabis, current and new customers have approached Greenway to potentially cultivate their trusted genetics. The Company has begun cultivation trials to test for high THC values and exceptional yields. Preliminary results have exceeded expectations and produced THC as high as 30%. These potential contracts provide an avenue for reputable peers to scale up, while providing Greenway with consistent revenues with the increased square footage.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy the securities in the United States nor shall there be any sale of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the “1933 Act”), or any state securities laws and may not be offered or sold in the United States unless registered under the 1933 Act and any applicable securities laws of any state of the United States or an applicable exemption from the registration requirements is available.

About Greenway

Greenway Greenhouse Cannabis Corporation is a federally licensed cultivator for the Canadian cannabis marketplace. Greenway is headquartered in Kingsville, Ontario, and leverages its agriculture and cannabis expertise in its aspiration to be a leading cannabis cultivator in Canada. More information can be found on Greenway.ca and updates can be followed on Instagram, Twitter, Facebook, and LinkedIn.

The CSE has in no way passed upon the merits of the business of the Company and has neither approved nor disapproved the contents of this news release and accepts no responsibility for the adequacy or accuracy hereof.

Cautionary Note Regarding Forward-Looking Statements

This news release contains forward-looking statements that constitute forward-looking information (collectively, “forward-looking statements”) within the meaning of applicable Canadian securities legislation. All statements in this news release that are not purely historical statements of fact are forward-looking statements and include statements regarding the Offering and the intended use of proceeds thereof, and the Company’s beliefs, plans, expectations, future, strategy, objectives, goals and targets, the development of future operations, and orientations regarding the future as of the date of this news release. Although the Company believes that such statements are reasonable and reflect expectations of future developments and other factors which management believes to be reasonable and relevant, the Company can give no assurance that such expectations will prove to be correct. Forward-looking statements are typically identified by words such as: “believes”, “expects”, “aim”, “anticipates”, “intends”, “estimates”, “plans”, “may”, “should”, “would”, “will”, “potential”, “scheduled” or variations of such words and phrases and similar expressions, which, by their nature, refer to future events or results that may, could, would, might or will occur or be taken or achieved.

Forward-looking statements involve known and unknown risks, assumptions, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to differ materially from any future results, performance or achievements expressed or implied by the forward-looking statements, and includes those risks described in the Company’s final prospectus dated September 3, 2021, a copy of which is available under the Company’s profile at www.sedar.com. Forward-looking statements are made as of the date of this news release and, unless required by applicable law, the Company assumes no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those projected in these forward-looking statements.

SOURCE Greenway Greenhouse Cannabis Corporation

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

LANGLEY, BC / ACCESSWIRE / August 17, 2022 / Adastra Holdings Ltd. (CSE:XTRX)(FRA:D2EP) (“Adastra” or the “Company”), a leading cannabis company focused on processing, product development, sales, organoleptic testing and analytical testing, is pleased to announce it has received its Medical Sales License from Health Canada which now authorizes Adastra to sell cannabinoid-containing products that are formulated for and distributed to the medical cannabis market.

With its Medical Sales License, Adastra is now authorized to:

• Sell cannabis extracts and dried cannabis to medical cannabis patients and licensed health practitioners; and
• Develop a broad range of products classified as cannabis extracts including:
  • Inhaled (vaporizer cartridge and shatter),
  • Ingested (tincture, oil, capsule, soft gel and oral spray), and
  • Other (suppository).

“This license marks another milestone for Adastra as we see a significant market opportunity for plant-based, natural medical remedies,” said Michael Forbes, Chief Executive Officer of Adastra. “We are excited to now produce and distribute cannabis product formats, designed for the medical market as Canada once again re-forms this patient-focused market that was the foundation for federal legalization. With my background in healthcare and strong ties to the medical community – including some of Canada’s largest pharmacy distributors and pharmacies – Adastra’s ability to produce and sell to the re-emerging and established medical market positions us to leverage our PerceiveMD clinics for direct-to-patient sales and pharmacy sales. Adastra has the added advantage through our PerceiveMD clinics to work directly with medical patients and collaborate with practitioners in developing plant-based alternative remedies designed for the medical cannabis market.”

Adastra’s Medical Sales License will enable the Company to maximize the full potential of PerceiveMD, Adastra’s wholly-owned platform, that assesses patients seeking alternative treatments and remedies and provides documentation to enable access.

“We continue to see an uptick in the therapeutic use of cannabis for symptom relief – everything from cancer, menopause, stress, depression, anxiety and so on,” Forbes added. “There is less stigma and more awareness today than ever before about the potential healing and symptom relief qualities of cannabis. We believe we’ll continue to see a rise in popularity of cannabis for medicinal purposes and we are positioning Adastra to capture and serve this significant market.”

The global medical cannabis market is projected to grow to $248.42 billion by 2030 at a 31.97% CAGR according to a recent report by Market Research Future. ¹

Adastra expects to start producing medical format cannabis products, specifically CBD tinctures by January 2023. The Company is currently exploring medical distribution platforms for Canadian sales and plans to formulate products based on recommendations from practitioners and patients in its established network.

Note 1: https://ca.finance.yahoo.com/news/medical-marijuana-market-worth-usd-160000093.html

About Adastra Holdings Ltd.
Adastra is a leading manufacturer and supplier of innovative ethnobotanical and cannabis science products designed for the adult-use, medical markets and forward-looking therapeutic applications. Adastra is recognized as a high-capacity processor and co-manufacturer throughout Canada. Adastra acquired 100% of the legacy-built brand Phyto Extractions in September 2021. The brand is well-known for its cannabis concentrate products, available on shelves at over 1,400 adult-use retailers across the country. The Company also operates Adastra Labs, a 13,500 sq. ft. agricultural-scale Health Canada licensed facility located in Langley, British Columbia, focused on extraction, distillation, and manufacturing of cannabis-derived products. Adastra has successfully taken steps in becoming a licensed cultivator, tester, extractor, and seller of controlled substances, including Psilocybin and Psilocin, by applying for a Controlled Substances Dealer’s License, which is under review by Health Canada. Pending Health Canada approval, Adastra is poised to be a drug formulation and development leader in this emerging sector. In addition, the acquisition of 1225140 B.C. Ltd., doing business as PerceiveMD, Adastra operates a multidisciplinary manufacturer for medical cannabis and psychedelic therapies, working alongside practitioners and healthcare professionals within the regulated environment to help create efficacious remedies that address the actual needs of patients. For more information, visit: www.adastraholdings.ca.

Contacts
Michael Forbes, CEO, Corporate Secretary & Director
(778) 715 5011,
[email protected]

Stephanie Martens, Investor Relations
[email protected]

Forward-Looking Information

This news release contains forward-looking information within the meaning of Canadian securities legislation concerning the business of the Company. Forward-looking information is based on certain key expectations and assumptions made by the management of the Company. Although the Company believes that the expectations and assumptions on which such forward looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because the Company can give no assurance that they will prove to be correct. Forward looking information in this news release includes statements regarding, but not limited to: (i) the expected activities that the Company may conduct with a Medical Sales License; (ii) the ability of the Company to leverage its existing clinics for direct-to-patient and pharmacy sales through its ability to sell to the growing and established medical market; (iii) the expectation that the Company will start producing medical cannabis products by January 2023; and (iv) pending approvals, Adastra is poised to be a drug formulation and development leader in controlled substances. There are numerous risks and uncertainties that could cause actual results and the Company’s plans and objectives to differ materially from those expressed in the forward-looking information. Important factors that could cause actual results to differ materially from those expressed in the forward-looking information include: the availability of a qualified workforce; changes in regulations or licensing affecting the Company’s business; reduced demand for cannabis and cannabis related products; reductions in the Company’s retail space and store locations; and other factors beyond the control of the Company. These and all subsequent written and oral forward-looking information are based on estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice. Except as required by law, the Company does not intend to update these forward-looking statements.

SOURCE: Adastra Holdings Ltd.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

New Canadian Markets Include Northwest Territories, New Brunswick, Yukon, and Newfoundland and Labrador

DELTA, British Columbia, July 25, 2022 (GLOBE NEWSWIRE) — Today, Pure Sunfarms Corp. (“Pure Sunfarms”), a wholly owned subsidiary of Village Farms International, Inc. (Nasdaq: VFF), announces its launch into additional Canadian markets: Yukon, Northwest Territories, New Brunswick, and in the weeks ahead, Newfoundland and Labrador.

Pure Sunfarms is now present in ten provinces and territories, which cover 98 per cent of total legal cannabis sales in Canada. Both Northern and Atlantic Canada are experiencing increases in retail cannabis sales, with the northern territories growing 42 per cent year-over-year in the first quarter of 2022, and Atlantic Canada as a whole showing 5 per cent growth year over year.* Pure Sunfarms is looking forward to supporting the growth of cannabis industries within these communities by building strong performance for retailers with Pure Sunfarms sought-after products.

“As Canada’s favourite flower brand, consumers in Northern and Atlantic Canada have been asking about Pure Sunfarms products for a while – and now, we’re so happy we can supply them,” said Mandesh Dosanjh, President & CEO, Pure Sunfarms. “Our commitment to quality and level of customer support will now extend to these regions, homes to communities that have welcomed us with open arms, and that we are very excited to serve.”

Products from Pure Sunfarms that will be available to consumers in Northern and Atlantic Canada include: dried flower, pre-rolls, vapes, and oils. Product types, strain selections, and format sizes will vary by province and territory.

• Yukon: Dried flower (Black Cherry Punch, Blue Dream, Pink Kush, Pure Sun CBD, Indica, Sativa); pre-ground (Diesel Kush, Pink Berry); pre-rolls (Blue Dream, D. Bubba, Pink Kush); vapes (Blueberry Kush 510, Black Cherry Punch 510, THC Distillate 510); oils (CBD Oil 30:1)
• Northwest Territories: Dried flower (Black Cherry Punch, Pink Kush, Jet Fuel Gelato); pre-rolls (Pink Kush, Jet Fuel Gelato); vapes (THC Distillate 510)
• New Brunswick: Dried flower (Jet Fuel Gelato)
• Newfoundland and Labrador: Dried flower (Pink Kush, Jet Fuel Gelato, Pure Sun CBD); pre-rolls (Pink Kush)

Pure Sunfarms product will be available for Yukon, Northwest Territories, New Brunswick, and Newfoundland and Labrador consumers to purchase from participating licensed retailers in their communities or by ordering online from the legal distributor in their respective region: Yukon Liquor Corporation (YLC), Northwest Territories Liquor and Cannabis Commission (NTLCC), Cannabis NB, and Cannabis NL.

*Statistics Canada. Table 20-10-0008-01 Retail trade sales by province and territory.

About Pure Sunfarms

Pure Sunfarms is one of the largest cannabis operations in the world with 2.2 million square feet of greenhouse space in Delta, British Columbia. The company currently operates within 1.65 million square feet, and has capacity to produce, sell and distribute 112,500 kilograms of high-quality, BC-grown dried flower annually for Canadian recreational and international markets, with the ability to expand annual output to 150,000 kilograms as needed. The company brings together decades of agricultural and legacy cultivation experience with best-in-class, large scale operational expertise, and is Canada’s top-selling brand.

Pure Sunfarms products are available in Ontario, British Columbia, Alberta, Saskatchewan, Manitoba, Yukon, Northwest Territories, New Brunswick, and Newfoundland and Labrador at participating retailers and online through each region’s respective distributor where applicable. Pure Sunfarms also provides cannabis to its affiliate ROSE LifeScience in Québec, other licensed producers in Canada and is EU GMP certified to export product internationally.

Pure Sunfarms is the licensed producer of record for Pure Sunfarms, The Original Fraser Valley Weed Co. and is Cookies sun-grown partner in Canada. Pure Sunfarms is a wholly owned subsidiary of Village Farms International, Inc. (Nasdaq: VFF).

www.puresunfarms.com

Media Contact

Danielle Allore
Communications Manager
[email protected]

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

LAS VEGAS, NV / ACCESSWIRE / April 14, 2022 / Planet 13 Holdings Inc. (CSE:PLTH)(OTCQX:PLNHF) (“Planet 13” or the “Company“),a leading vertically-integrated multi-state cannabis company, announced the start of expansion of its Nevada cultivation facility adding 22,000 square feet of cultivation space to fuel in-house product growth.

“We’ve seen incredible consumer support for our brands like TRENDI and HaHa which have risen to among the top selling brands in their respective categories in Nevada. The only thing that has limited Medizin, our popular premium flower brand, from joining them at the top of the leaderboard has been supply constraints. Our lack of supply has historically led to us selling out every harvest, leaving our customers wanting more,” said Larry Scheffler, Co-CEO of Planet 13. “The expansion of our Nevada cultivation facility will allow us to better satisfy customer demand for our premium flower and continue to grow our in-house brands share of sales.”

For more information on Planet 13, visit the investor website.

About Planet 13
Planet 13 (www.planet13holdings.com) is a vertically integrated cannabis company, with award-winning cultivation, production and dispensary operations in Las Vegas and dispensary operations in Orange County, California. Planet 13 also holds a medical marijuana treatment center license in Florida and a 49% interest in Planet 13 Illinois which won a lottery for a Social-Equity Justice Involved dispensing license in the Chicago-region of Illinois. Planet 13’s mission is to build a recognizable global brand known for world-class dispensary operations and a creator of innovative cannabis products. Planet 13’s shares trade on the Canadian Securities Exchange (CSE) under the symbol PLTH and OTCQX under the symbol PLNHF.

Cautionary Note Regarding Forward-Looking Information
This news release contains “forward-looking information” and “forward-looking statements” (collectively, “forward-looking statements”) within the meaning of applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as “expects”, or “does not expect”, “is expected”, “anticipates” or “does not anticipate”, “plans”, “budget”, “scheduled”, “forecasts”, “estimates”, “believes” or “intends” or variations of such words and phrases or stating that certain actions, events or results “may” or “could”, “would”, “might” or “will” be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements. In this news release, forward looking-statements relate to the Company’s plan to expand cultivation facility and satisfy consumer demand.

These forward-looking statements are based on reasonable assumptions and estimates of management of the Company at the time such statements were made. Actual future results may differ materially as forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to materially differ from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors, among other things, include: risks associated with COVID-19 and other infectious diseases presenting as major health issues; fluctuations in general macroeconomic conditions; fluctuations in securities markets; expectations regarding the size of the Nevada and California cannabis market or other states in which the Company may operate and changing consumer habits; the ability of the Company to successfully achieve its business objectives; plans for expansion; political and social uncertainties; inability to obtain adequate insurance to cover risks and hazards; and the presence of laws and regulations that may impose restrictions on cultivation, production, distribution and sale of cannabis and cannabis related products in states in which we operate or contemplate future operations; and employee relations. Although the forward-looking statements contained in this news release are based upon what management of the Company believes, or believed at the time, to be reasonable assumptions, the Company cannot assure shareholders that actual results will be consistent with such forward-looking statements, as there may be other factors that cause results not to be as anticipated, estimated or intended. Readers should not place undue reliance on the forward-looking statements and information contained in this news release. The Company assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law.

The Company is indirectly involved in the manufacture, possession, use, sale and distribution of cannabis in the recreational and medicinal cannabis marketplace in the United States through licensed subsidiary entities in states that have legalized marijuana operations, however, these activities are currently illegal under United States federal law. Additional information regarding this and other risks and uncertainties relating to the Company’s business, including COVID-19, are contained under the heading “Risk Factors” and elsewhere in the Company’s Form 10-K dated March 28, 2022 as filed on its issuer profile on SEDAR at www.sedar.com.

No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein.

For further inquiries, please contact:
LodeRock Advisors Inc., Planet 13 Investor Relations
[email protected]

Robert Groesbeck or Larry Scheffler
Co-Chief Executive Officers
[email protected]

SOURCE: Planet 13 Holdings

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

Fully Executed Agreements establish new hub for cannabis delivery in Hollywood Hills as well as partnership in popular restaurant trend as exclusive provider for on-site cannabis event space

NEW YORK, March 30, 2022 (GLOBE NEWSWIRE) — via InvestorWire – Sugarmade, Inc. (OTC Pink: SGMD) (“Sugarmade”, “SGMD” or the “Company”) an emerging leader in the licensed cannabis sector, is pleased to announce the signing of Definitive Agreements (the “Agreements”) related to the Company’s expansion, including the establishment of majority ownership in a fully licensed new Hollywood cannabis delivery hub (the “Delivery Hub”) located on the world famous Sunset Strip as well as a minority stake in an expanding reservation-only restaurant brand with an adjacent private event space which will include cannabis consumption.

The location of the Delivery Hub and restaurant will be located on the world-famous Sunset Strip. The Company will also have majority ownership control over a brand-new cannabis retail distribution hub that provides delivery radius coverage in the affluent neighborhoods of the West Hollywood Hills. This new delivery zone does not overlap with Sugarmade’s existing Los Angeles delivery footprint.

“This investment lands us on the ground floor of a new concept for cannabis distribution in the world’s biggest cannabis marketplace,” stated Jimmy Chan, CEO of Sugarmade.

According to the Agreements, Sugarmade will take in one hundred percent (100%) of all profits from the new Delivery Hub until the Company has made back all its capital investment, after which time the Company will take in 51% of all profits from this Delivery hub location going forward.

In addition, Sugarmade teamed up with Boulevard Hospitality Group (“BHG”), best known for operating Yamashiro, the iconic Hollywood Hills restaurant which is over 100 years old, to be its first choice provider of cannabis for BHG’s expansion into its future cannabis-only venues.

Chan added, “Through these Agreements, we are simultaneously adding a new cannabis end market with future growth potential, doubling our delivery coverage in the LA metro area, and creating a new and more diversified revenue profile. We believe all of these steps represent strong potential drivers for shareholder value.”

About Sugarmade
Sugarmade, Inc. (OTC Pink: SGMD) is a product and branding marketing company investing in operations and technologies with disruptive potential. Our Brand portfolio includes CarryOutsupplies.com, SugarRush, NUG Avenue, Lemon Glow and Budcars.

For more information, please visit www.Sugarmade.com.

FORWARD-LOOKING STATEMENTS: This release contains “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements also may be included in other publicly available documents issued by the Company and in oral statements made by our officers and representatives from time to time. These forward-looking statements are intended to provide management’s current expectations or plans for our future operating and financial performance, based on assumptions currently believed to be valid. They can be identified by the use of words such as “anticipate,” “intend,” “plan,” “goal,” “seek,” “believe,” “project,” “estimate,” “expect,” “strategy,” “future,” “likely,” “may,” “should,” “would,” “could,” “will” and other words of similar meaning in connection with a discussion of future operating or financial performance. Examples of forward-looking statements include, among others, statements relating to future sales, earnings, cash flows, results of operations, uses of cash and other measures of financial performance.

Because forward-looking statements relate to the future, they are subject to inherent risks, uncertainties and other factors that may cause the Company’s actual results and financial condition to differ materially from those expressed or implied in the forward-looking statements. Such risks, uncertainties and other factors include, among others, such as but not limited to; economic conditions, changes in the laws or regulations, demand for products and services of the company, the effects of competition, uncontrollable forces of nature and other factors that could cause actual results to differ materially from those projected or represented in the forward-looking statements.

Any forward-looking information provided in this release should be considered with these factors in mind. We assume no obligation to update any forward-looking statements contained in this report.

Corporate Contact:
Jimmy Chan
+1-(888)-982-1628
[email protected]

Investor Relations Contact:
EDM Media, LLC
https://edm.media

Corporate Communications:
InvestorBrandNetwork (IBN)
Los Angeles, California
www.InvestorBrandNetwork.com
310.299.1717 Office
[email protected]

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

Cannabis Dispensary Franchise Primed for Record Growth After Successful 2021 with Eight New Partners Expanding the Brand Across Six New States

PHOENIX, Feb. 11, 2022 /PRNewswire/ — Unity Rd., the cannabis dispensary franchise from Item 9 Labs Corp. (OTCQX: INLB), is prepped for momentous growth with new franchise partners, acquisitions and openings. After a successful year of eight signed agreements for expansion into six new states, the brand is well-positioned to build off this performance in an optimistic 2022.

Maine, Michigan, New Jersey, South Dakota, and Virginia were some of the states to see franchise growth in 2021 – and the industry itself grew with five more states legalizing either medicinal or adult-use cannabis last year. With several states preparing to legalize cannabis through legislative bills and ballot measures this year, more opportunities will soon be available and market forecasts show U.S. cannabis sales will reach $50 billion by 2026.

“Cannabis is one of the fastest-growing industries in the world and we are at the forefront, as a pioneer leading the charge,” said Andrew Bowden, CEO of Item 9 Labs Corp. “Heading into 2022, we believe all our efforts will accelerate as we see licenses and permits go through and new Unity Rd. openings taking place nationwide.”

A major brand milestone was hit in June with the opening of Unity Rd.’s first cannabis franchise shop in Boulder, Colorado owned by a father-and-son team. Stacked with a roster of strong development, Unity Rd. also solidified deals in New Jersey and Virginia, while announcing its expansion throughout Maine, and most recently signed its first agreement in South Dakota.

Another success the franchise company saw last year was the launch of a national dispensary acquisition program which offers a solution for prospective entrepreneurs seeking immediate entry into the cannabis industry. Through corporate acquisitions, this program converts dispensaries into Unity Rd. shops that can be sold to an existing or future franchise partner. This initiative allows for another avenue to keep cannabis dispensary ownership local, which is at the core of Unity Rd.’s mission and will be a key focal point this year.

In October, Item 9 Labs Corp. executed an Asset Purchase Agreement for the first shop in this program, an existing dispensary license and storefront in Adams County, Colorado. The company is currently awaiting regulatory approval by Colorado’s Marijuana Enforcement Division (the “MED”) and expects the shop to be operational in the first half of 2022.

“We truly strengthened our foundation this past year, and now we will continue to educate and build awareness of our franchise opportunity,” added Unity Rd.’s Chief Franchise Officer Mike Weinberger. “We have seen increased interest from prospective franchise partners and are starting to open more shops, but we are not taking our pedal off the gas because more entrepreneurs need to know that the complex cannabis industry and franchising can exist as one – and that is Unity Rd.”

An industry trailblazer, Unity Rd. has set the stage as the first national cannabis dispensary franchise model in the United States. This continues to be recognized by the franchise industry, as Unity Rd. recently became the first of its kind to be named a member of the International Franchise Association (IFA). The cannabis dispensary franchise also landed a place on Franchise Dictionary Magazine’s TOP 100 Game Changers for 2021 and Franchise Journal Magazine’s list of 2021 Top Brands.

Unity Rd. offers a guided route for cannabis entrepreneurs looking to enter and navigate the complex cannabis industry. The dispensary franchise’s time-tested Standard Operating Procedures (SOPs) and dedicated team, with a combined 120+ years of cannabis experience, direct franchise partners through every operational function of the business, whether it be securing a license or assisting with cash flow, product selection or changing regulations. The marijuana dispensary franchise is actively seeking qualified partners who would benefit from the systems, processes and ongoing support the franchise offers. Currently, Unity Rd. has multiple agreements signed with nearly 20 entrepreneurial groups who are in various stages of development nationwide.

To learn more about the Unity Rd. franchise opportunity, contact [email protected], call 720-923-5262 or visit unityrd.com.

About Unity Rd.:
Unity Rd. is bridging the two previously disconnected worlds of cannabis and franchising. The industry trailblazer is the first to bring the cannabis dispensary franchise model to the United States—with duality of prowess in both industries to back it up. Built up from a collective 200 years in the legal cannabis industry and franchising, the company helps eager operators enter the complex industry with ease. The marijuana franchise pioneer offers its partners the knowledge, resources, and ongoing support needed to compliantly and successfully operate a dispensary. Launched in 2018, Unity Rd. has signed multiple agreements with nearly 20 entrepreneurial groups across the country. Recently, it was named one of the top cannabis retail leaders in the nation by MJBizDaily magazine and one of the “Best Cannabis Companies to Work For” in both the dispensary and cultivation categories in Cannabis Business Times’ elite 2020 list. The company is also the first cannabis business to earn a Franchise Times Dealmakers award. For more information, visit unityrd.com.

About Item 9 Labs Corp.
Item 9 Labs Corp. (OTCQX: INLB) is a vertically integrated cannabis operator and dispensary franchisor delivering premium products from its large-scale cultivation and production facilities in the United States. The award-winning Item 9 Labs brand specializes in best-in-class products and user experience across several cannabis categories. The company also offers a unique dispensary franchise model through the national Unity Rd. retail brand. Easing barriers to entry, the franchise provides an opportunity for both new and existing dispensary owners to leverage the knowledge, resources, and ongoing support needed to thrive in their state compliantly and successfully. Item 9 Labs brings the best industry practices to markets nationwide through distinctive retail experience, cultivation capabilities, and product innovation. The veteran management team combines a diverse skill set with deep experience in the cannabis sector, franchising, and the capital markets to lead a new generation of public cannabis companies that provide transparency, consistency, and well-being. Headquartered in Arizona, the company is currently expanding its operations space up to 640,000+ square feet on its 50-acre site, one of the largest properties in Arizona zoned to grow and cultivate flower. For additional information, visit item9labscorp.com.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such statements involve risks and uncertainties, including, but not limited to, risks and effects of legal and administrative proceedings and governmental regulation, especially in a foreign country, future financial and operational results, competition, general economic conditions, proposed transactions that are not legally binding obligations of the company and the ability to manage and continue growth. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual outcomes may vary materially from those indicated. Important factors that could cause actual results to differ materially from the forward-looking statements we make in this news release include the introduction of new technology, market conditions and those set forth in reports or documents we file from time to time with the SEC. We undertake no obligation to revise or update such statements to reflect current events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

Media Contact:
Marisa Beaumont
Fishman PR
[email protected]
847-945-1300

Investor Contact:
Item 9 Labs Corp.
[email protected]
800-403-1140

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

Vancouver, British Columbia–(Newsfile Corp. – February 3, 2022) – Nextleaf Solutions Ltd. (CSE: OILS) (OTCQB: OILFF) (FSE: L0MA) (“Nextleaf“, “OILS“, or the “Company“), a federally regulated manufacturer and distributor of cannabis vapes and oils, is pleased to announce it has received approval from the Ontario Cannabis Store (“OCS“) to list the Company’s Glacial Gold products in Ontario. Wholly-owned by the Province of Ontario, the OCS is the sole distributor in the province and all Ontario retailers must purchase their product inventory through the OCS.

“We are thrilled for British Columbia’s #1 selling CBD focused vape to be available at cannabis retailers across Ontario this Spring,” said Paul Pedersen, CEO of Nextleaf. “Expanding distribution of Glacial Gold products into Ontario is a significant milestone for our Company and sets the stage for significant growth of our branded product sales. By leveraging Nextleaf’s patented distillation technology, Glacial Gold vapes and oils deliver unparalleled value to consumers.”

Glacial Gold Available in Ontario Spring 2022

To view an enhanced version of this graphic, please visit:
https://orders.newsfilecorp.com/files/5347/112658_72822c65e4e2e85e_001full.jpg

The OCS is listing Nextleaf’s SKUs in two core product categories; vape cartridges and distilled oils. The first products available this spring will be from Nextleaf’s award-winning prohibition-era brand Glacial Gold, including the Anytime Vape, and Distilled 30/30 Blend Oil.

Glacial Gold Anytime Vapes are formulated with a balanced 1:1 THC and CBD profile for consumers looking for a more moderate, anytime vape. Glacial Gold Distilled 30/30 Blend Oil features high-purity CBD and THC distillates in a base of organic coconut MCT oil for a premium consumption experience, without premium pricing. A clean tasting, and neutral oil allowing for greater flexibility in use and consumption occasions.

Glacial Gold products are expected to be available at retail stores across Ontario and at osc.ca starting May 2022. Learn more at www.Glacial.Gold.

Nextleaf Introduces New Vape Flavours in B.C.

Nextleaf’s wholly-owned subsidiary, Nextleaf Labs Ltd. (“Nextleaf Labs“), has completed a shipment to the British Columbia Liquor and Distribution Branch of its three new Glacial Gold vape SKUs, including two new flavours: Sunshine Punch and Sparkling Grape. The Company anticipates the product will be available for B.C. retailers to order in early February. Nextleaf Labs is a Top-10 supplier of vapes and oils in British Columbia¹.

Nextleaf Ships Glacial Gold Vapes and Distilled Oils to Nova Scotia

Nextleaf Labs has completed its first shipments of Glacial Gold CBD and THC products to the Nova Scotia Liquor Corporation (“NSLC“). Glacial Gold vapes and distilled oils will be available in February across Nova Scotia through NSLC cannabis stores.

Nextleaf Engages National Sales Agency

Nextleaf is pleased to announce it has engaged Cannavolve Inc. (“Cannavolve“) to provide field coverage at cannabis retailers and support the national rollout of Glacial Gold products. “Our field team, our co-founder & Partner Kye Melchert, and I are all extremely excited that Nextleaf has chosen Cannavolve as their national sales agency. We have a strong track record of building brands in Canada, and we look forward to being a part of Glacial Gold brand’s path to growth,” said Trace Hanlon, Partner and Director of Cannavolve.

Cannavolve has a wide network throughout every major provincial market in Canada and the partnership will help Nextleaf achieve further route-to-market efficiencies and position its award-winning prohibition-era brand, Glacial Gold as a national leader in the vape and CBD oil categories.

About Cannavolve Inc.

Cannavolve is an independent, recreational cannabis sales and marketing agency established to represent Licensed Producers and Licensed Processors of quality-assured cannabis, and global suppliers of cannabis accessories. Cannavolve offers a choice of national or regional licensed non-medicinal retail field coverage, innovative, compliant marketing solutions, and government board navigation services. By leveraging analytic data, extensive B2B experience and a best-in-class sales team, Cannavolve delivers results for our suppliers and retail partners through custom tailored commercial strategies and execution. Cannavolve operates nationally with regional offices in Montreal, Toronto, and Vancouver. For more information, visit www.Cannavolve.ca.

About Nextleaf®

Nextleaf is a federally regulated manufacturer and distributor of cannabis vapes and oils under its award-winning prohibition-era brand, Glacial Gold. The Company’s multi-patented ingredient processing technology transforms cannabis and hemp biomass into high-purity distillate at an industrial scale. Nextleaf is a low-cost producer of cannabis oils, and supplies THC and CBD ingredients to qualified wholesale partners across Canada. Nextleaf is the first publicly traded company to be issued a U.S. patent for the industrial extraction and purification of cannabinoids. The Company has been issued 17 U.S. patents, and over 90 patents globally, on cannabinoid processing including distillation and acetylation. Nextleaf develops proprietary cannabinoid-based formulations and delivery technology through its Health Canada Research Licence with sensory evaluation of cannabis via human testing. For more information, visit www.nextleafsolutions.com and www.Glacial.Gold.

Nextleaf Solutions trades as OILS on the Canadian Securities Exchange, OILFF on the OTCQB Market in the United States, and L0MA on the Frankfurt Stock Exchange.

Follow the Company across social platforms: Twitter, LinkedIn, Facebook, Instagram.

Follow Glacial Gold across social platforms: Instagram, Twitter, Facebook.

For more information please contact:
Jason McBride, Corporate Development
604-283-2301 (ext. 219)
[email protected]

On behalf of the Board of Directors of the Company,
Paul Pedersen, CEO

Forward Looking Statements

Certain statements contained in this press release constitute “forward-looking statements” within the meaning of applicable securities laws. All statements other than statements of historical fact contained in this press release, including, without limitation, those regarding the terms of the Offering, the anticipated closing date of the Offering, the use of proceeds of the Offering, the Company’s strategy, plans, objectives, goals and targets, and any statements preceded by, followed by or that include the words “believe”, “expect”, “aim”, “intend”, “plan”, “continue”, “will”, “may”, “would”, “anticipate”, “estimate”, “forecast”, “predict”, “project”, “seek”, “should” or similar expressions or the negative thereof, are forward-looking statements. These statements are not historical facts but instead represent only the Company’s expectations, estimates and projections regarding future events. These statements are not guarantees of future performance and involve assumptions, risks and uncertainties that are difficult to predict. Therefore, actual results may differ materially from what is expressed, implied or forecasted in such forward-looking statements. Additional factors that could cause actual results, performance or achievements to differ materially include, but are not limited to the risk factors discussed in the Company’s MD&A for the most recent fiscal period. Management provides forward-looking statements because it believes they provide useful information to investors when considering their investment objectives and cautions investors not to place undue reliance on forward-looking information. Consequently, all of the forward-looking statements made in this press release are qualified by these cautionary statements and other cautionary statements or factors contained herein, and there can be no assurance that the actual results or developments will be realized or, even if substantially realized, that they will have the expected consequences to, or effects on, the Company. These forward-looking statements are made as of the date of this press release and the Company assumes no obligation to update or revise them to reflect subsequent information, events or circumstances or otherwise, except as required by law. The Canadian Securities Exchange has not reviewed or approved the contents of this press release.

¹ Units sold according to BC wholesale data (Q4 2021)

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.